Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
News|Articles|November 9, 2026
FDA Flashback: Hematologic Cancer Decisions and News From October 2026
Author(s)OncLive Staff
Fact checked by: Riley Kandel
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement
Catch a glimpse of the hematologic malignancy–related FDA decisions and announcements from October 2026, including the approval of a noncovalent BTK inhibitor in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the submission of a biologics license application (BLA) for a BCMA-directed bispecific T-cell engager in relapsed/refractory multiple myeloma, the final approval of a generic BCL-2 inhibitor in CLL/SLL and newly diagnosed acute myeloid leukemia (AML), a breakthrough therapy designation for a menin inhibitor in relapsed/refractory KMT2A-rearranged acute leukemia, and an orphan drug designation for a PLK1 inhibitor in chronic myelomonocytic leukemia (CMML).
Related to this article
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
The FDA granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma.
Advertisement
Advertisement